Advance your cardiovascular knowledge at morning and evening educational events.
Non-accredited educational events are offered by companies and organizations at various venues throughout Chicago. Make plans now to attend these events to advance your cardiovascular knowledge.*
Friday, March 23
5:30 p.m.–9:30 p.m. | Optimizing PCI Outcomes: A Vision for 2012
Saturday, March 24
6:30 p.m.–9:00 p.m. | Evaluating Recent Clinical Trial Data in the Secondary Prevention of Acute Coronary Syndrome (ACS)
Sunday, March 25
5:30 a.m.–7:30 a.m. | Pathways of Disease Progression in Heart Failure: What Can Galectin-3 Tell Us?
5:30 a.m.–7:30 a.m. | 3rd Annual Massachusetts General Hospital Optical Coherence Tomography (OCT) Symposium:
A Comprehensive Review of OCT in Today’s Cath Lab Environment
6:30 p.m.–8:15 p.m. | Baroreflex Activation Therapy (BAT) for Resistant Hypertension & Heart Failure: A Novel Approach to Cardiovascular Treatment
6:30 p.m.–9:00 p.m. | SYMPLICITY HTN-3 Trial: Evaluating Renal Denervation for Resistant Hypertension
Presentation schedules are current as of March 9, 2012, and are subject to change.
Friday, March 23 | 5:30 p.m.–9:30 p.m.
Swissôtel Chicago (Zurich Ballroom), 323 East Wacker Drive, Chicago, IL 60601
This symposium will comprehensively cover the latest clinical and experimental breakthroughs in the percutaneous treatment of coronary artery disease. Those attending will be exposed to the latest clinical trial data on current and second-generation drug-eluting stent device-based therapies. Controversies, including resistance and selection, of antiplatelet therapy as adjunctive treatment with percutaneous intervention will be discussed along with the use of imaging tools and how to manage complex lesions. Utilizing both didactic and case-based presentation, attendees will be exposed to the latest clinical and evidence-based medicine options to optimize patient outcomes in the treatment of coronary artery disease.
This symposium is designed for the interventional, invasive, general cardiologist, and other physicians with interests in interventional vascular medicine.
For more information and to register, please visit www.pcioutcomes.com.
5:30 p.m.–6:41 p.m. | Session I: Overarching Issues (Moderators: Stone and Colombo)
5:30 p.m.–5:42 p.m. | Controversy 1: Current Drug-Eluting Stents Are Not Only More Effective, But Are Safer Than Bare Metal Stents and Should Be Used in >90% of (Stented) Patients (Stone)
5:42 p.m.–5:52 p.m. | Controversy 2, Part A: The Case for Surgery in Patients with Complex Coronary Artery Disease (Serruys)
5:52 p.m.–6:02 p.m. | Controversy 2, Part B: The Case for PCI in Patients with Complex Coronary Artery Disease (Colombo)
6:02 p.m.–6:14 p.m. | Controversy 3: In an Era of Increasing Governmental and Payor Oversight, Who is Appropriate (and Not Appropriate) for PCI (Patel)
6:14 p.m.–6:29 p.m. | Moderated Discussion
6:29 p.m.–6:41 p.m. | Case Presentations: Multivessel PCI: Justification and Outcomes
6:29 p.m.–6:41 p.m. | Case #1 (Schampaert)
6:41 p.m.–8:20 p.m. | Session II: Optimizing PCI (Moderators: Leon and Serruys)
6:41 p.m.–6:53 p.m. | Optimizing Pharmacology Before, During and After PCI (Ohman)
6:53 p.m.–7:05 p.m. | Optimizing Stent Selection (A Patient- and Lesion-Specific Approach) (Leon)
7:05 p.m.–7:17 p.m. | Procedural Guidance with FFR (Fearon)
7:17 p.m.–7:29 p.m. | Imaging Guidance with IVUS (Mintz)
7:29 p.m.–7:41 p.m. | Prevention and Treatment of Stent Thrombosis (Kirtane)
7:41 p.m.–7:56 p.m. | Moderated Discussion
7:56 p.m.–8:20 p.m. | Case Presentations: Complex PCI
7:56 p.m.–8:08 p.m. | Case #2: Integrated Use of IVUS and FFR (Park)
8:08 p.m.–8:20 p.m. | Case #3: A Patient with Recurrent Stent Thrombosis (Mehran)
8:20 p.m.–9:30 p.m. | Session III: Complex PCI: Technique, Tips and Tricks (Moderators: Teirstein and Grube)
8:20 p.m.–8:32 p.m. | PCI of Bifurcations and Trifurcations (Louvard)
8:32 p.m.–8:44 p.m. | PCI in NSTEMI and STEMI: Essentials of Pharmacology (Gibson)
8:44 p.m.–8:54 p.m. | Hemodynamic Support: In Whom, When, and Which (Popma)
8:54 p.m.–9:06 p.m. | Moderated Discussion
9:06 p.m.–9:30 p.m. | Case Presentations
9:06 p.m.–9:18 p.m. | Case #4: High-Risk and Complex PCI in a Patient with LVEF <20% (Grube)
9:18 p.m.–9:30 p.m. | Case #5: My Worst Complication of the Last Five Years (Teirstein)
Martin B. Leon, MD—NewYork-Presbyterian Hospital/Columbia University Medical Center; New York, NY
Gregg W. Stone, MD—NewYork-Presbyterian Hospital/Columbia University Medical Center New York, NY
Antonio Colombo, MD—Columbus Hospital/San Raffaele Hospital; Milan, Italy
George D. Dangas, MD, PhD—Mount Sinai Medical Center; New York, NY
William F. Fearon, MD—Stanford University Medical Center; Stanford, CA
C. Michael Gibson, MD—Beth Israel Deaconess Medical Center; Boston, MA
Eberhard Grube, MD—University Hospital Bonn; Bonn, Germany
Ajay J. Kirtane, MD, SM—NewYork-Presbyterian Hospital/Columbia University Medical Center; New York, NY
Yves Louvard, MD—Institut Hospitalier Jacques Cartier; Massy, France
Akiko Maehara, MD—Cardiovascular Research Foundation; New York, NY
Brij Maini, MD—Pinnacle Health System; Harrisburg, PA
Roxana Mehran, MD—Mount Sinai Medical Center; New York, NY
Gary S. Mintz, MD—Cardiovascular Research Foundation; Washington, DC
E. Magnus Ohman, MD—Duke University Medical Center; Durham, NC
Seung-Jung Park, MD, PhD—Asan Medical Center; Seoul, South Korea
Manesh R. Patel, MD—Duke University Medical Center; Durham, NC
Jeffrey J. Popma, MD—Beth Israel Deaconess Medical Center; Boston, MA
Erick Schampaert, MD—Hopital du Sacre-Coeur de Montreal; Montreal, Canada
Patrick W. Serruys, MD, PhD—Thoraxcenter; Rotterdam, The Netherlands
Paul S. Teirstein, MD—Scripps Clinic and Research Foundation; La Jolla, CA
Giora Weisz, MD—NewYork-Presbyterian Hospital/Columbia University Medical Center; New York, NY
Mathew Williams, MD—NewYork-Presbyterian Hospital/Columbia University Medical Center; New York, NY
Return to top
Saturday, March 24 | 6:30 p.m.–9:00 p.m.
Hyatt Regency McCormick Place (Grand Ballroom), 2233 South Martin Luther King Drive, Chicago, IL 60616
Use of dual antiplatelet therapy (aspirin plus a thienopyridine) in the setting of acute coronary syndrome (ACS) reduces both short- and long-term adverse cardiovascular events. However, there is still a 10% risk for cardiovascular death and other ischemic complications in the year following ACS. As coronary thrombosis is known to be composed of both platelets and fibrin, it has been hypothesized that the use of antithrombotic therapy may be effective in reducing the residual risk following ACS. This program will review the past and current standard of care for secondary prevention for patients with established coronary disease as well as the rationale for the use of novel oral anticoagulants to reduce the risk of residual recurrent ischemic events following ACS.
Upon completion of this activity, participants will be able to:
• Evaluate antithrombotic strategies to reduce residual risk for patients following ACS
• Review clinical trial results of novel oral anticoagulants in the secondary prevention of thromboembolic events following ACS
• Assess how the use of oral anticoagulation may change current standards of care in patients experiencing ACS
This presentation is intended for cardiologists, internal medicine physicians, family practitioners and other healthcare professionals involved in the management of patients experiencing an ACS.
Please join us for this dinner symposium and preregister at http://symposia.theheart.org/conferences/acs2012.
6:30 p.m.–7:00 p.m. | Registration and Dinner Reception
7:00 p.m.–7:10 p.m. | Introduction and Overview (Gibson)
7:10 p.m.–7:30 p.m. | An Oral History of Anticoagulation in Secondary Prevention: Defining Residual Risk and the Role of Thrombin (Verheugt)
7:30 p.m.–7:50 p.m. | Appraising the Role of Oral Anticoagulation in the Secondary Prevention of ACS: Initial Experiences (Alexander)
7:50 p.m.–8:10 p.m. | Surveying the Atlas: Reviewing Recent and Late-Breaking Data of Oral Anticoagulation in ACS (Gibson)
8:10 p.m.–8:30 p.m. | Current State of Equipoise Regarding Upstream Management: The Need to Evaluate the Efficacy of Upstream Therapies Further in the Context of Novel Agents (Ohman)
8:30 p.m.–9:00 p.m. | Putting It All Together: Panel Discussion and Clinical Pearls
C. Michael Gibson, MD—Chairman, PERFUSE Study Group; Chairman, WikiDoc Foundation; Chief of Clinical Research CV Division, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School; Consulting Professor in Medicine, Duke University School of Medicine; Durham, NC
John H. Alexander, MD, MHS—Associate Professor of Medicine, Division of Cardiovascular Medicine, Duke Clinical Research Institute, Duke University Medical Center; Durham, NC
Freek W. A. Verheugt, MD—Professor of Cardiology, Chairman, Department of Cardiology, Onze Lieve Vrouwe Gasthuis; Amsterdam, The Netherlands
E. Magnus Ohman, MD—Professor of Medicine, Associate Director, Duke Heart Center - Cardiology Clinics; Director, Program for Advanced Coronary Disease, Duke Clinical Research Institute, Duke University Medical Center; Durham, NC
Return to top
Sunday, March 25 | 5:30 a.m.–7:30 a.m.
Hyatt Regency McCormick Place (Room CC12BCD), 2233 South Martin Luther King Drive, Chicago, IL 60616
Galectin-3 as a Mediator of Cardiac Fibrosis—Review of In-Vitro and Pre-Clinical Experiments (de Boer)
Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community—Results of the Framingham Heart Study (Ho)
Galectin-3 in Relation to Prognosis and Effect of Valsartan Treatment—Results of the Val-HeFT Trial (Anand)
Galectin-3 as an Aid in Prioritizing Candidates for CRT Treatment—Results of the MADIT-CRT Study (Stein)
Summary and Concluding Remarks (Cleland)
Professor John G.F. Cleland, MD, FACC—University of Hull; United Kingdom
Inder Anand, MD, FACC, FRCP, DPhil—University of Minnesota and Minneapolis VA Medical Center; Minneapolis, MN
Rudolf A. de Boer, MD, PhD—University Medical Center Groningen; The Netherlands
Jennifer E. Ho, MD—National Heart, Lung, and Blood Institute’s Framingham Heart Study; Framingham, MA
Kenneth Stein, MD, FACC—Senior Vice President and Chief Medical Officer, Cardiac Rhythm Management at Boston Scientific; Minneapolis, MN
Return to top
Sunday, March 25 | 5:30 a.m.–7:30 a.m.
Chicago Marriott Magnificent Mile, 540 North Michigan Avenue, Chicago, IL 60611
This case-based review session, presented by leading physician experts on OCT, will demonstrate the clinical utility of OCT in a variety of lesion subsets.
5:30 a.m.–5:50 a.m. | Welcome/Updates on MGH OCT Registry (Jang)
5:50 a.m.–6:10 a.m. | How to Use OCT to Facilitate PCI (Prati)
6:10 a.m.–6:25 a.m. | 3 Vessel OCT Imaging in ACS (Kato)
6:25 a.m.–6:45 a.m. | MGH Case Review (Neoatherosclerosis/Stent Complications) (Yonetsu/Kim)
6:45 a.m.–7:00 a.m. | OCT Adaption at the Mayo Clinic (Prasad)
7:00 a.m.–7:15 a.m. | Is OCT a Research Tool or Clinical Device? (Costa)
7:15 a.m.–7:30 a.m. | Importance of OCT Registry/Closing Comments/Q&A (Narula)
Ik Kyung Jang, MD, PhD, FACC—Professor of Medicine, Harvard Medical School; Interventional Cardiology, Massachusetts General Hospital; Director, Cardiology Laboratory for Integrative Physiology & Imaging (CLIPI); Boston, MA
Jagat Narula, MD, PhD, FACC—Philip J. and Harriet L. Goodhart Chair in Cardiology, Professor of Medicine, Associate Dean for Global Health, Mount Sinai School of Medicine; Director, Cardiovascular Imaging Program, Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health; New York, NY
Marco A. Costa, MD, PhD, FACC, FSCAI—Professor of Medicine; Director, Interventional Cardiovascular Center, Director, Center for Research and Innovation; Harrington-McLaughlin Heart and Vascular Institute; University Hospitals, Case Western Reserve University; Cleveland, OH
Koji Kato, MD, PhD—Research Fellow, Cardiology Division, Massachusetts General Hospital, Harvard Medical School; Boston, MA
Soo Joong Kim, MD, PhD—Associate Professor of Medicine, Kyung Hee University Hospital; Seoul, Korea; Research Fellow, Cardiology Division, Massachusetts General Hospital, Harvard Medical School; Boston, MA
Francesco Prati, MD—Interventional Cardiology, San Giovanni Hospital, CLI Foundation; Rome, Italy
Abhiram Prasad, MD—Professor of Medicine, Division of Cardiovascular Diseases, Mayo Clinic; Rochester, MN
Taishi Yonetsu, MD—Research Fellow, Cardiology Division, Massachusetts General Hospital, Harvard Medical School; Boston, MA
Return to top
Sunday, March 25 | 6:30 p.m.–8:15 p.m.
Four Seasons Hotel Chicago, 120 East Delaware Place, Chicago, IL 60611
Now, a significant body of evidence is available for an alternative therapeutic approach for both resistant hypertension and heart failure: baroreflex activation therapy, also known as BAT.
BAT is the only therapeutic approach that activates the baroreflex, the body’s master regulator of hemodynamics, to restore sympatho-vagal balance. Unlike medical therapy or targeted ablation, BAT differentially impacts end organs including the heart, kidneys, arteries and veins to normalize cardiovascular function. BAT clinical results are encouraging for the treatment of resistant hypertension, and very interesting for the treatment of systolic and diastolic heart failure.
This presentation is intended for cardiologists, interventionalists and heart failure specialists.
Please RSVP and register at www.BATSatelliteSymposium.com.
Eugene Braunwald, MD—Distinguished Hersey Professor, Harvard Medical School; Founding Chairman, TIMI Study Group, Brigham and Women’s Hospital
Alberto Zanchetti, MD—Scientific Director, Istituto Auxologico of Milan; Emeritus Professor of Internal Medicine, University of Milan
Prof. John D. Bisognano, MD—Director of Outpatient Cardiology, University of Rochester Medical Center
Prof. George Bakris, MD—Director, Hypertension Center, The University of Chicago Hospitals
Prof. Hermann Haller, MD—Director, Department of Nephrology at Hannover Medical School in Germany
Prof. Hani N. Sabbah, MD—Professor of Medicine, Wayne State University; Director of Cardiovascular Research, Henry Ford Health System
Prof. Uta Hoppe, MD—Director, Department of Internal Medicine II, Paracelsus University Salzburg, Austria
Prof. William T. Abraham, MD—Director, Division of Cardiovascular Medicine, The Ohio State University
Return to top
Sunday, March 25 | 6:30 p.m.–9 p.m.
InterContinental Chicago (Grand Ballroom, 7th Floor), 505 North Michigan Avenue, Chicago, IL
• Resistant Hypertension and the Role of the Sympathetic Nervous System
• Introduction to Renal Denervation (RDN)
• Clinical Evidence from SYMPLICITY HTN-1 and HTN-2 Trials
• The Design of SYMPLICITY HTN-3 Trial
• Current Status of SYMPLICITY HTN-3 Trial
This presentation is intended for general cardiologists, nephrologists, general practitioners, primary care physicians, hypertension specialists, interventional cardiologists and interventional radiologists.
Transportation will be provided from McCormick Place to the InterContinental Chicago. Seating is limited—register now at www.RDNsatellitesymposia.com.
Henry Krum—SYMPLICITY HTN-1 Lead Author
Murray Esler—SYMPLICITY HTN-2 Lead Author
Suzanne Oparil—SYMPLICITY HTN-3 Steering Committee
David Kandzari—SYMPLICITY HTN-3 Steering Committee
Return to top
*These events are not part of the official ACC Annual Scientific Session & Expo and/or ACC-i2 with TCT, as planned by their Program Committees. These events do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.